Minerva Neurosciences, Inc. (NASDAQ:NERV – Free Report) – Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Minerva Neurosciences in a research note issued to investors on Thursday, May 2nd. HC Wainwright analyst D. Tsao anticipates that the biopharmaceutical company will post earnings per share of ($1.03) for the quarter. HC Wainwright currently has a “Neutral” rating and a $7.00 target price on the stock. The consensus estimate for Minerva Neurosciences’ current full-year earnings is ($3.57) per share. HC Wainwright also issued estimates for Minerva Neurosciences’ Q2 2025 earnings at ($0.90) EPS, Q3 2025 earnings at ($0.76) EPS and Q4 2025 earnings at ($0.92) EPS.
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last posted its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.31).
Get Our Latest Stock Analysis on NERV
Minerva Neurosciences Stock Performance
Shares of Minerva Neurosciences stock opened at $2.37 on Friday. The business has a 50-day simple moving average of $2.66 and a 200-day simple moving average of $5.30. The company has a market cap of $16.57 million, a PE ratio of -0.53 and a beta of 0.27. Minerva Neurosciences has a one year low of $2.29 and a one year high of $13.49.
About Minerva Neurosciences
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
Further Reading
- Five stocks we like better than Minerva Neurosciences
- Using the MarketBeat Stock Split Calculator
- MarketBeat Week in Review – 4/29 – 5/3
- Consumer Staples Stocks, Explained
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.